Audit: QRS - Salacia reticulata for Health & Longevity
Audit conducted on 14/08/2026 03:33 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol cells against ER lines 313/315/325, time-to-effect against ER lines 365 and 160, benefit and risk tiers against the ER section headings, gates against ER lines 270–295, all ten monitoring rows and the cadence against ER lines 393–406, and the five qualitative items against ER lines 410–414. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The conflicted fat-loss evidence is carried as “Human evidence for fat loss conflicts” (line 522), and the ER’s untested items stay in the Speculative tiers. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | The ER’s “Avoid combining” (other α-glucosidase inhibitors) and “Absolute pause” (elective surgery) are carried as Contraindications rather than downgraded to Key Interactions. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefit- and Risk-Modifying Factors (ER lines 200–208, 256–266) are not surfaced anywhere; gates draw only from Key Interactions & Contraindications. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT identifiers, author names or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Wording is lifted or lightly condensed from the ER throughout, including its British spellings (“haemoglobin”, “favourable”, “standardised”). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Numeric ranges are given for doses and every monitoring target, alongside plain-language framing in the At-A-Glance. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is presented as labelled data cells and tiered lists, not as instructions to a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No advisory verbs; the footer disclaimer is the template’s own. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “should” or equivalent in the QRS’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns appear anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | The technical terms retained (α-glucosidase inhibitors, HOMA-IR, eGFR, ALT) are decision- or measurement-critical and come verbatim from the ER. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | A 446-line ER is condensed to short noun phrases; no cell carries a full sentence of explanation. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no direct address anywhere in the document. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Monitoring targets are the ER’s optimal functional ranges (HbA1c 4.8–5.4%, HOMA-IR under 1.0), not conventional clinical cut-offs. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The protocol assumes per-meal dosing split across two or three meals and daily capillary or continuous glucose tracking for two weeks. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | A ten-marker laboratory panel plus body-composition tracking is well beyond general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The At-A-Glance closes on the two caveats that matter most to an optimiser — unreliable product identity and no data beyond three months. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Longevity” appears only in the canonical topic; “anti-aging” appears nowhere. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | The plainer terms in the At-A-Glance (“table sugar”, “loose stools”) are the ER Conclusion’s own wording and are required there by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All fifteen fixed strings match the template byte for byte (QRS lines 445, 488, 530, 560, 575, 606, 632, 637–639, 780, and the eight tier <strong> labels). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Every one of the template’s 34 variable names is present; the only additions are the expected numbered expansions of marker_#_* (ten rows) and qualitative_item_# (five items). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A normalised structural diff against the template shows no change outside the variable spans; website="evidence_review", website="audit" and website="full_review" are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | The three protocol labels are the ER’s bold labels verbatim: “Standard practitioner dose”, “Timing relative to the meal”, “Split versus single dosing” (ER lines 313, 315, 325). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Monitoring row labels match the ER biomarker table exactly; benefit and risk items match the ER #### headings; time-to-effect labels map to ER headings (“Post-Meal Glucose”, “Glycated Haemoglobin”, “Body Fat”). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji in the file; the ER’s “⚠️ Conflicted” marker on the body-fat benefit was correctly stripped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than transcribed: the twelve-bullet ER protocol yields three cells, the nine-bullet interaction list yields seven one-line gate items, and the cadence paragraph is compressed to a single clause chain. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after <!doctype html> on line 1 and before the template comment on line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the descriptive text sits on line 2, before the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | It is inside an HTML comment; no metadata value is repeated in the header, footer or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, and it contains a colon, so the quoting is required. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: salacia_reticulata_2026-0814-0150_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0814-0320, in the required format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word carrying no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version, with no context-window or tier qualifier appended. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 states salacia_reticulata_2026-0814-0150_Opus_QRS.html, which is the file’s actual name on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys, including git_user: evipedia-3 and git_issue: 5136; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Salacia reticulata for Health & Longevity - Quick Reference Sheet”, matching the ER’s canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Salacia reticulata for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421 shows 08/14/2026, the correct MM/DD/YYYY rendering of 2026-0814-0320. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header block (lines 415–428) is structurally identical to the template; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Four sentences covering mechanism, the best-supported effect, the sustained effect, the dominant harm and the two decision-relevant caveats — all drawn from ER lines 438–442. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Enzyme blockade and post-meal flattening ← ER 438; small average-glucose drop ← ER 438; gas/bloating/loose stools ← ER 440; unreliable product identity and nothing beyond three months ← ER 440/442. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “HbA1c” is rendered as “the average blood sugar marker” and “α-glucosidase” as “the gut enzymes splitting starch and table sugar”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No author name, year, enrolment figure or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | The ER’s percentages (14%/22% glucose AUC) are replaced by the qualitative “flattening” and “a small drop”. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items trace to ER lines 270–295. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | The six populations of ER lines 290–295 plus the two avoid-grade bullets — “Avoid combining” for other α-glucosidase inhibitors (ER 272) and “Absolute pause” for elective surgery (ER 286). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight discrete <li> elements on lines 563–570. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No dashes or trailing clauses survive; the ER’s “in whom no data exist” was correctly stripped from the under-18 item (ER 295 → QRS 568). |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Preserved: “without continuous glucose monitoring”, “with any degree of stricture”, “below 20 kg/m²”, “(acarbose, miglitol, voglibose)”, “(stop at least two weeks before)”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify such populations (ER lines 288–295). |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items trace to ER lines 270–284. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All nine ER interaction bullets are accounted for: seven here, and the α-glucosidase-inhibitor and elective-surgery bullets in Contraindications, with no duplication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Seven discrete <li> elements on lines 578–596. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER “Caution —” / “Monitor —” clause and its mitigation sentence is stripped; only the agent names remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All five ER drug lists are carried intact, including the seven-item supplement list and <em>Gymnema sylvestre</em> italicisation. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER identifies nine such interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from the ER Therapeutic Protocol bullets at lines 313, 315 and 325. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, meal timing and per-meal splitting are the three decisions that determine whether the extract works at all; the remaining nine ER bullets are contextual or conditional. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section carries twelve bullets, so all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans are populated; e.g. action_1 gives “240–500 mg” with “giving 500–1,500 mg per day”, both from ER line 313. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Post-meal glucose (ER 365), HbA1c (ER 365) and body fat mass (ER 160) are the only three outcomes for which the ER gives a time course. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Order follows the ER’s own tiers: High (post-meal glucose), then the two Medium benefits, with the better-evidenced HbA1c ahead of the conflicted fat-mass result. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine spans are populated; “6 weeks–3 months / Matches red-cell turnover” reproduces ER line 365. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information at line 365, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All nine items map one-to-one onto the ER #### benefit headings at lines 142–196. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans are present and populated (lines 532–553), each carrying its tier’s items. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Every Magnitude: paragraph, trial name and conflict-of-interest note is dropped; items are bare noun phrases. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any of the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers carry items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All six items map one-to-one onto the ER #### risk headings at lines 216–252. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans are present and populated (lines 608–626), each carrying its tier’s items. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | The breath-hydrogen figures, the glibenclamide dose-change signal and the rat post-implantation-loss data are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses remain in any of the four risk spans. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER risk tiers carry items, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows and cadence come from the ER Monitoring Protocol & Defining Success section, lines 393–406. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER table rows are present in order, with targets reproduced exactly (e.g. “Above 90 mL/min/1.73 m²”, “Under 20 U/L men, under 17 U/L women”). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 770–774 carry the daily-for-two-weeks, 12-week, six-monthly and annual body-composition schedule of ER line 393. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items come from the ER’s “Qualitative markers worth tracking” list, lines 410–414. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers are present and carried verbatim, in the ER’s order. |
Issues 14/08/2026 03:33
Pass rate 100.00%. No issues found.
Issues 14/08/2026 03:25
- 12.3 / 12.4 — Qualifier retained in benefits:
benefits_medium(lines 537–538) keeps the parenthetical qualifier “(conflicted)” on “reduced body fat and body weight”, although the Benefits section requires qualifiers and parenthetical content to be stripped because the tier already encodes evidence strength.
Fixes 14/08/2026 03:25
- 12.3 / 12.4 — Qualifier stripped from benefits: Removed the parenthetical “(conflicted)” from
benefits_medium, leaving “Lower glycated haemoglobin with continued use; reduced body fat and body weight”.